Joint Drugs Controller under CBI net for allegedly taking bribe to waive off clinical trial of Biocon's Insulin Aspart injection

Denying allegations, a Biocon Biologics spokesperson said, "All our product approvals are legitimate and backed by science and clinical data. Our bAspart is approved in Europe and many other countries.";

Published On 2022-06-21 06:19 GMT | Update On 2022-06-21 06:19 GMT

New Delhi: The CBI on Monday apprehended Joint Drugs Controller S Eswara Reddy for allegedly receiving a Rs 4 lakh bribe to waive phase-three clinical trial of Insulin Aspart injection, an underdevelopment product of Biocon Biologics, officials said.

After getting inputs about an exchange of bribe, the CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, L Praveen Kumar, Associate Vice President and Head-National Regulatory Affairs (NRA), Biocon Biologics Limited, Bangalore; and Dinesh Dua, Director at Synergy Network India Private Limited, among others.

The CBI, which was working on the input for over a month, carried out a raid and Dua was caught giving Rs 4 lakh bribe to Reddy of the total promised amount of Rs 9 lakh on behalf of Biocon Biologics, a subsidiary of Kiran Majumder Shaw-led Biocon, officials said.

"Phase 3 clinical trial is an important regulatory mechanism to assess the safety of a pharma product. Any attempt to waive them off can have serious public health safety repercussions," an official said.

The CBI has also named Guljit Sethi alias Guljit Chaudhary, Director, Bioinnovat Research Services Private Limited, Delhi; and Animesh Kumar, Assistant Drug Inspector (ADI), CDSCO, New Delhi, in its FIR.

The CBI has alleged that the regulatory work of Biocon Biologics was looked after by Guljit Sethi of Bioinnovat Research Services Private Ltd.

Bioinnovat and Synergy Network have business dealings hence Dua agreed to make the bribe payment, the probe agency has alleged.

Denying allegations, a Biocon Biologics spokesperson said, "All our product approvals are legitimate and backed by science and clinical data. Our bAspart is approved in Europe and many other countries."

"We follow due regulatory process for all our product approvals by DCGI. The entire application process in India is online and all meeting minutes are in public domain," he said.

The spokesperson said the company is cooperating with the investigation agency.

A similar statement was also tweeted by Biocon Executive Chairperson Kiran Mazumdar Shaw.

The CBI has alleged that executives of Biocon Biologics were trying to exert undue influence on officers of Central Drugs Standard Control Organisation (CDSCO) under the Directorate General of Health Services, Ministry of Health and Family Welfare, to waive the phase 3 trial of 'Insulin Aspart Injection', officials said.

It was alleged that they agreed to pay a bribe of Rs 9 lakh to Reddy for "favourably processing" three files related to Biocon Biologics and also to favourably recommend the file of "Insulin Aspart injection" to the Subject Expert Committee (SEC) meeting, they said.

"The CBI laid a trap wherein the JDC of CDSCO was caught while accepting a bribe of Rs 4 lakh from the director of a Delhi-based private company. The said director was also caught," CBI spokesperson R C Joshi said.

The CBI conducted searches at 11 places in Delhi, Noida, Gurugram, Patna and Bengaluru which led to the recovery of incriminating documents and articles, he said.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Joint Drugs Controller under CBI net for allegedly taking bribe to waive off clinical trial of Biocon's Insulin Aspart injection

Denying allegations, a Biocon Biologics spokesperson said, "All our product approvals are legitimate and backed by science and clinical data. Our bAspart is approved in Europe and many other countries.";

Similar News

Roche gets negative EMA Committee opinion on Elevidys CMA for 3-7 year olds with Duchenne muscular dystrophy

Expert Committee Clears Ravenbhel to Begin Resmetirom Phase 3 Trial, Asks for BE Data First

Menopause relief drug: USFDA extends review period for Bayer Elinzanetant

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Troikaa's Fast-Acting Paracetamol Shot Hits Regulatory Hurdle, CDSCO Panel Seeks More Data

Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma

Pharma Firm Ignored Safety Gaps Before Deadly Blast, Paid Rs 32 Cr To Victims, Parliament Informed

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma